Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com
StockNews.com upgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning. Separately, HC Wainwright reiterated a “buy” rating and issued a $7.50 price objective on shares of Akebia Therapeutics in a research report on Wednesday, October 23rd. Get […]
10 Jan 06:48 · The Markets Daily